Atlas Capital Advisors Inc. Cuts Stock Position in Organon & Co. (NYSE:OGN)

Atlas Capital Advisors Inc. lowered its position in Organon & Co. (NYSE:OGN - Free Report) by 85.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,546 shares of the company's stock after selling 20,625 shares during the quarter. Atlas Capital Advisors Inc.'s holdings in Organon & Co. were worth $53,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of OGN. Barclays PLC increased its holdings in shares of Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company's stock worth $2,285,000 after buying an additional 84,136 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in Organon & Co. during the 4th quarter worth approximately $2,263,000. Wedmont Private Capital increased its stake in Organon & Co. by 453.4% in the 4th quarter. Wedmont Private Capital now owns 100,539 shares of the company's stock worth $1,594,000 after purchasing an additional 82,372 shares during the period. Sippican Capital Advisors lifted its position in Organon & Co. by 138.7% in the fourth quarter. Sippican Capital Advisors now owns 36,352 shares of the company's stock valued at $542,000 after purchasing an additional 21,122 shares during the last quarter. Finally, Systematic Financial Management LP boosted its stake in shares of Organon & Co. by 5,097.3% during the third quarter. Systematic Financial Management LP now owns 37,940 shares of the company's stock valued at $726,000 after purchasing an additional 37,210 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Remove Ads

Organon & Co. Trading Down 2.3 %

Shares of OGN traded down $0.27 during trading hours on Friday, reaching $11.17. 5,055,884 shares of the company traded hands, compared to its average volume of 2,651,096. Organon & Co. has a 12 month low of $10.94 and a 12 month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company's fifty day moving average price is $14.64 and its two-hundred day moving average price is $15.67. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of 3.35, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 10.03%. Organon & Co.'s payout ratio is 33.63%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on OGN shares. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, Morgan Stanley dropped their target price on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $20.60.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.